The pediatric studies initiative: After 15 years have we reached the limits of the law?

Clinical Therapeutics

Volumn 36, Issue 2, 2014, Pages 156-162

  Milne, Christopher Paul ^a   Davis, Jonathan ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

carrot and stick; incentives; neonates; pediatric formulations; pediatrics; research and development

Indexed keywords

CARROT AND STICK; INCENTIVES; NEONATES; PEDIATRIC FORMULATIONS; PEDIATRICS; RESEARCH AND DEVELOPMENT;

CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INFANT, NEWBORN; PEDIATRICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84894208114     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.11.007     Document Type: Review

References (14)

1. A.E. Mulberg, S.A. Silber, and J.N. van den Anker Pediatric Drug Development: Concepts and Applications 2nd ed 2013 Wiley & Sons Ltd Hoboken, NJ
2. J.A. DiMasi Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications Clin Ther 35 2013 808 818
3. A.N. Sachs, D. Avant, C.S. Lee, W. Rodriguez, and D. Murphy Pediatric information in drug product labeling JAMA 307 2012 1914 1915
4. Yao L. FDA takes steps to encourage pediatric drug studies. FDA Voice. August 26, 2013. http://blogs.fda.gov/fdavoice/index.php/tag/food-and-drug- administration-safety-and-innovation-act-fdasia/. Accessed October 25, 2013.
5. M.J. Field, L.K. Ellinger, and T.F. Boat IOM review of FDA-approved biologics labeled or studied for pediatric use Pediatrics 131 2013 328 335
6. Tufts Center for the Study of Drug Development database based on FDA Pediatric Labeling Information DatabaseBoston, MA: Tufts University; 1963
7. S.K. Pasquali, W.K. Lam, K. Chiswell, A.R. Kemper, and J.S. Li Status of the pediatric clinical trials enterprise: an analysis of the US ClinicalTrials.gov Registry Pediatrics 130 2012 e1269 e1277
8. M. Tassinari Pediatric Regulations 2012: Permanent Laws and New Provisions Under FDASIA December 4, 2012 Pediatric and Maternal Health Staff, Office of New Drugs, Food and Drug Administration Silver Spring, MD
9. National Academies of Sciences. Preterm Births Cost U.S. $26 Billion a Year; Multidisciplinary Research Effort Needed to Prevent Early Births. July 13, 2006. http://www8.nationalacademies.org/onpinews/newsitem.aspx? recordid=11622. Accessed October 25, 2013.
10. G.J. Noel, J.N. Van Den Anker, D. Lombardi, and R. Ward Improving drug formulations for neonates: making a big difference in our smallest patients J Pediatr 161 2012 947 948
11. J.M. Davis, E.M. Connor, and A.J. Wood The need for rigorous evidence of medication use in preterm infants: is it time for a neonatal rule? JAMA 308 2012 1435 1436
12. V. Sharma US FDA invites public to nominate drugs for pediatric development Scrip Clin Rev August 30, 2012
13. Institute of Medicine. Safe and effective medicines for children: pediatric studies conducted under BPCA and PREA. http://www.iom.edu/~/media/ Files/Report%20Files/2012/Safe-and-Effective-Medicines-for-Children/ safeeffectivemeds-RB.pdf. Accessed October 25, 2013.
14. D. Murphy Pediatric Academic Societies: 2013: How Do We Optimize Global Trial Development and Why Networks Are So Critical May 2013 Food and Drug Administration Silver Spring, MD